

Oculodentodigital Dysplasia

A Cause of Hypomyelinating Leukodystrophy in Adults


Mackenzie A. Michell-Robinson, MSc, Stefanie Perrier, HBSc, Cassandra Lucia, BA, Luan T. Tran, MSc, Isabelle Thiffault, MSc, PhD, Wolfgang Köhler, MD, and Geneviève Bernard, MD, MSc, FRCPC

Neurology® 2022;98:675-677. doi:10.1212/WNL.0000000000200228

Correspondence

Dr. Bernard
genevieve.bernard@mcgill.ca

Figure 1 Patient's MRI and Teeth



(A) MRI reveals thin corpus callosum and mild vermian atrophy. Axial T1 and T2 images show diffuse hypomyelination (B, C) with typical involvement of the posterior limb of the internal capsule (C, arrow), pons (corticospinal tracts, medial lemniscus, raphe pontis), and cerebellar peduncles (E) with hypointensity of the rolandic cortex (D, arrow) and dentate nucleus. (F) Dental abnormalities.


A middle-aged patient presented with mild facial dysmorphisms, small teeth with enamel hypoplasia, progressive gait disturbances, memory problems, and history of syndactyly, corrected in early childhood. MRI showed a hypomyelination pattern compatible with oculodentodigital dysplasia (ODDD)^{1,2} (Figure 1). Ophthalmic findings revealed severe bilateral myopia. Exome sequencing revealed a heterozygous *GJA1* missense variant (*p.Gly138Asp*). The patient's mother (deceased) had developed slowly progressive neurodegeneration, ataxia, and seizures. MRI (age 80) revealed extensive leukodystrophic changes (Figure 2). ODDD diagnosis is often missed, highlighting the importance of clinical suspicion, MRI, and molecular testing in adult patients with facial, dental, and neurologic clinical features.

From the Departments of Neurology and Neurosurgery (M.A.M.-R., S.P., C.L., L.T.T., G.B.), Pediatrics (G.B.), and Human Genetics (G.B.), McGill University; Child Health and Human Development Program (M.A.M.-R., S.P., C.L., L.T.T., G.B.), Research Institute of the McGill University Health Centre, Montréal, Canada; Center for Pediatric Genomic Medicine (I.T.) and Department of Pathology (I.T.), Children's Mercy Hospital; Faculty of Medicine (I.T.), University of Missouri, Kansas City; Department of Neurology (W.K.), Leukodystrophy Center, University of Leipzig Medical Center, Germany; and Department of Specialized Medicine (G.B.), Division of Medical Genetics, Montreal Children's Hospital and McGill University Health Centre, Montréal, Canada.

Go to [Neurology.org/N](https://www.neurology.org/N) for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

Submitted and editor reviewed. The handling editor was Jose Merino, MD, MPhil.

Figure 2 Mother's MRI



(A) Thin corpus callosum, ventriculomegaly (atrophy), and cerebellar vermis atrophy on sagittal T2 image. (B) Axial T1 image shows ventriculomegaly and significant posterior white matter atrophy. Fluid-attenuated inversion recovery images reveal diffuse white matter hyperintensity (C, D) involving the posterior limb of the internal capsule (C, arrow) and corticospinal tracts and medial lemniscus in the pons (E).

This study was approved by the Montreal Children's Hospital and McGill University Health Center research ethics boards (11-105-PED; 2019-4972).

Acknowledgment

The authors thank the patient and his family for participation; McGill University and Genome Quebec Innovation Center; and Compute Canada (computeCanada.ca) for support.

Study Funding

Canadian Institutes for Health Research (project grant 426534 and 201610PJT-377869).

Disclosure

G. Bernard was a consultant for Passage Bio Inc. and Ionis; serves on the scientific advisory board of the Pelizaeus Merzbacher Foundation; is the Chair of the Medical Advisory Board of the United Leukodystrophy Foundation; is on the editorial board of *Neurology Genetics*, *Frontiers in Neurology Neurogenetics*, and *Journal of Medical Genetics*; is a site investigator for the GM1 gangliosidosis and Krabbe gene therapy trials of Passage Bio, Alexander disease trial of Ionis, metachromatic leukodystrophy trial of Shire/Takeda, and adrenoleukodystrophy/hematopoietic stem cell transplantation natural history study of Bluebird Bio; and is a sub-I for the Hunter syndrome gene therapy trial of REGENXBIO. W. Koehler receives research support from Alexion, Bluebird Bio, and MedDay; is consultant and coinvestigator for the AMN disease trial of Minoryx; and serves on scientific advisory boards of the United Leukodystrophy Foundation, the European Leukodystrophy Association, and the Myelin Project Germany. G. Bernard has received the Clinical Research

Scholar Junior 1 award from the Fonds de Recherche du Québec-Santé (FRQS) (2012–2016), the New Investigator Salary Award from the Canadian Institutes of Health Research (2017–2022), and the Clinical Research Scholar Senior from the FRQS (2022–2025). S. Perrier is supported by the FRQS Doctoral Scholarship, the Fondation du Grand défi Pierre Lavoie Doctoral Scholarship, the McGill Faculty of Medicine F.S.B. Miller Fellowship, and the Research Institute of the McGill University Health Centre Desjardins Studentship in Child Health Research. M. Michell-Robinson is supported by the Vanier Canada Graduate Scholarship and the McGill University Faculty of Medicine. The other authors have no disclosures to report. Go to [Neurology.org/N](https://www.neurology.org/N) for full disclosures.

Appendix Authors

Name	Location	Contribution
Mackenzie A Michell-Robinson, MSc	Department of Neurology and Neurosurgery, McGill University; Child Health and Human Development Program, Research Institute of the McGill University Health Centre, Montréal, QC, Canada	Drafting/revision of the manuscript for content, including medical writing for content
Stefanie Perrier, HBSc	Department of Neurology and Neurosurgery, McGill University; Child Health and Human Development Program, Research Institute of the McGill University Health Centre, Montréal, QC, Canada	Drafting/revision of the manuscript for content, including medical writing for content; Analysis or interpretation of data

Appendix (continued)

Name	Location	Contribution
Cassandra Lucia, BA	Department of Neurology and Neurosurgery, McGill University; Child Health and Human Development Program, Research Institute of the McGill University Health Centre, Montréal, QC, Canada	Drafting/revision of the manuscript for content, including medical writing for content
Luan T Tran, MSc	Department of Neurology and Neurosurgery, McGill University; Child Health and Human Development Program, Research Institute of the McGill University Health Centre, Montréal, QC, Canada	Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data
Isabelle Thiffault, MSc, PhD	Center for Pediatric Genomic Medicine, Children's Mercy Hospital; Faculty of Medicine, University of Missouri Kansas City; Department of Pathology, Children's Mercy Hospital, Kansas City, MO	Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Analysis or interpretation of data
Wolfgang Köhler, MD	Department of Neurology, Leukodystrophy Center, University of Leipzig Medical Center, Leipzig, Germany	Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Analysis or interpretation of data

Appendix (continued)

Name	Location	Contribution
Geneviève Bernard, MD, MSc, FRCPC	Department of Neurology and Neurosurgery, McGill University; Child Health and Human Development Program, Research Institute of the McGill University Health Centre; Department of Pediatrics, McGill University; Department of Human Genetics, McGill University; Department of Specialized Medicine, Division of Medical Genetics, Montreal Children's Hospital and McGill University Health Centre, Montréal, QC, Canada	Drafting/revision of the manuscript for content, including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data

References

1. Harting I, Karch S, Moog U, Seitz A, Pouwels PJW, Wolf NI. Oculodentodigital dysplasia: a hypomyelinating leukodystrophy with a characteristic MRI pattern of brain stem involvement. *Am J Neuroradiol.* 2019;40:903-907.
2. Paznekas WA, Boyadjiev SA, Shapiro RE, et al. Connexin 43 (GJA1) mutations cause the pleiotropic phenotype of oculodentodigital dysplasia. *Am J Hum Genet.* 2003;72:408-418.

Neurology® Online CME Program

Earn CME while reading *Neurology*. This program is available to AAN members and to online *Neurology* subscribers. Read the articles marked CME, go to Neurology.org, and click on the CME link. The American Academy of Neurology (AAN) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. *Neurology* is planned and produced in accordance with the ACCME Essentials. For more information, contact AAN Member Services at 800-879-1960.

Autoimmune Neurology Abstracts Sought for New AAN Summer Conference

The AAN is seeking scientific abstract submissions on topics related to autoimmune neurology for presentation at the new 2022 AAN Summer Conference: Autoimmune Neurology and Neurology Year in Review, which will take place July 15–16 in San Francisco, CA. Submission of previously presented or published work is encouraged if it is of interest to the field.

Learn more and submit your abstract by the May 3 deadline at AAN.com/SummerConference.